Eli Lilly Licenses Non-Opioid Pain Drug from Confo Therapeutics

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 8 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2768     ISSN: 1756-7874

Section: Licensing



Adding to its pain portfolio, Eli Lilly has entered into a global licensing agreement with Confo Therapeutics for the latter’s lead asset, CFTX-1554, a Phase I oral inhibitor of the angiotensin II type 2 receptor for the treatment of neuropathic pain...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details